Appendix

Human soluble ACE2 improves the effect of remdesivir in SARS-CoV-2 infection

Vanessa Monteil¹, Matheus Dyczynski²,³, Volker M Lauschke⁴, Hyesoo Kwon⁵, Gerald Wirnsberger⁶, Sonia Youhanna⁶, Haibo Zhang⁷, Arthur S.Slutsky⁷, Carmen Hurtado del Pozo⁸,⁹,¹⁰, Moritz Horn²,³, Nuria Montserrat⁸,⁹,¹⁰, Josef M. Penninger¹¹,¹², and Ali Mirazimi¹,⁵

Appendix Table S1
### Appendix Table S1: p-values for figures 1 and 3

| Figure and comparison                  | P value  |
|----------------------------------------|----------|
| 1A non-treated vs 4µM                  | 0.0028   |
| 1A non-treated vs 10µM                 | 0.0025   |
| 1A non-treated vs 20µM                 | 0.0024   |
| 1A non-treated vs 30µM                 | 0.0024   |
| 1A 4µM vs 10µM                        | 0.0242   |
| 1A 4µM vs 20µM                        | 0.0201   |
| 1A 4µM vs 30µM                        | 0.0201   |
| 1B non-treated vs hrsACE2 25µg/ml      | 0.0003   |
| 1B non-treated vs hrsACE2 50µg/ml      | 0.0002   |
| 1B non-treated vs hrsACE2 100µg/ml     | 0.0002   |
| 1B non-treated vs hrsACE2 200µg/ml     | 0.0002   |
| 3A non-treated vs hrsACE2              | <0.0001  |
| 3A non-treated vs Remd. 4µM            | <0.0001  |
| 3A non-treated vs Remd. 4µM + hrsACE2  | <0.0001  |
| 3A hrsACE2 vs Remd. 4µM + hrsACE2      | 0.0364   |
| 3A Remd. 4µM vs Remd. 4µM + hrsACE2   | 0.0023   |
| 3B non-treated vs hrsACE2             | 0.0035   |
| Condition                          | p-value |
|-----------------------------------|---------|
| 3B non-treated vs Remd. 4µM       | 0.0035  |
| 3B non-treated vs Remd. 4µM + hrsACE2 | 0.0035  |
| 3C hrsACE2 5µg/ml vs hrsACE2 5µg/ml + Remde. 4µM | 0.0376  |
| 3C Remd. 4µM vs Remd. 4µM + hrsACE2 5µg/ml | 0.0055  |
| 3C Remd. 4µM vs Remd. 4µM + hrsACE2 10µg/ml | 0.0044  |
| 3D Non-treated vs Remd. 4µM       | 0.0003  |
| 3D Non-treated vs hrsACE2 10g/ml + Remd. 4µM | 0.0003  |
| 3D Remd. 4µM vs Remd. 4µM + hrsACE2 10µg/ml | 0.0287  |
| 3D hrsACE2 10g/ml vs Remd 4µM + hrsACE2 10µg/ml | 0.0295  |
| 3E non-treated vs hrsACE2 5µg/ml  | 0.0060  |
| 3E non-treated vs hrsACE2 10µg/ml | 0.0059  |
| 3E non-treated vs hrsACE2 5µg/ml + Remd. 4µM | 0.0059  |
| 3E non-treated vs hrsACE2 10µg/ml + Remde 4µM | 0.0059  |
| 3E hrsACE2 5µg/ml vs hrsACE2 10µg/ml | 0.0491  |
| 3E Remd. 4µM vs Remd. 4µM + hrsACE2 5µg/ml | 0.0446  |
| 3E Remd. 4µM vs Remd. 4µM + hrsACE2 10µg/ml | 0.0443  |
| 3F non-treated vs hrsACE2 5µg/ml  | 0.0021  |
| 3F non-treated vs hrsACE2 10µg/ml | 0.0020  |
| Comparison                                             | p-value |
|--------------------------------------------------------|---------|
| 3F non-treated vs hrsACE2 5μg/ml + Remd. 4μM            | 0.0019  |
| 3F non-treated vs hrsACE2 10μg/ml + Remde 4μM          | 0.0019  |
| 3F Remd. 4μM vs Remd. 4μM + hrsACE2 5μg/ml             | 0.0235  |
| 3F Remd. 4μM vs Remd. 4μM + hrsACE2 10μg/ml           | 0.0234  |